Akeso logs Phase III success in second tumour type for ivonescimab

Summit is currently conducting various studies on ivonescimab across the solid tumour landscape, while the drug is under US review for NSCLC. Ivonescimab is currently in global clinical trials for various solid tumour indications, while being under US regulatory review for NSCLC. Ivonescimab is currently in global development for a range of solid tumour indications. Credit: Pikovit / Shutterstock.com. Summit Therapeutics’ $500m upfront bet on Akeso’s PD-1 x VEGF bispecific, ivonescimab, is looking increasingly well placed, with the latter having reported a second Phase III win for the drug through a Chinese study – this time in frontline, advanced biliary…

Source: Clinical Trials Arena